RT Journal Article
SR Electronic
T1 Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.06.21264641
DO 10.1101/2021.10.06.21264641
A1 Earnest, Rebecca
A1 Uddin, Rockib
A1 Matluk, Nicholas
A1 Renzette, Nicholas
A1 Siddle, Katherine J.
A1 Loreth, Christine
A1 Adams, Gordon
A1 Tomkins-Tinch, Christopher H.
A1 Petrone, Mary E.
A1 Rothman, Jessica E.
A1 Breban, Mallery I.
A1 Koch, Robert Tobias
A1 Billig, Kendall
A1 Fauver, Joseph R.
A1 Vogels, Chantal B.F.
A1 Turbett, Sarah
A1 Bilguvar, Kaya
A1 De Kumar, Bony
A1 Landry, Marie L.
A1 Peaper, David R.
A1 Kelly, Kevin
A1 Omerza, Greg
A1 Grieser, Heather
A1 Meak, Sim
A1 Martha, John
A1 Dewey, Hannah H.
A1 Kales, Susan
A1 Berenzy, Daniel
A1 Carpenter-Azevedo, Kristin
A1 King, Ewa
A1 Huard, Richard C.
A1 Smole, Sandra C.
A1 Brown, Catherine M.
A1 Fink, Timelia
A1 Lang, Andrew S.
A1 Gallagher, Glen R.
A1 Sabeti, Pardis C.
A1 Gabriel, Stacey
A1 MacInnis, Bronwyn L.
A1 New England Variant Investigation Team
A1 Tewhey, Ryan
A1 Adams, Mark D.
A1 Park, Daniel J.
A1 Lemieux, Jacob E.
A1 Grubaugh, Nathan D.
YR 2021
UL http://medrxiv.org/content/early/2021/10/07/2021.10.06.21264641.abstract
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant quickly rose to dominance in mid-2021, displacing other variants, including Alpha. Studies using data from the United Kingdom and India estimated that Delta was 40-80% more transmissible than Alpha, allowing Delta to become the globally dominant variant. However, it was unclear if the ostensible difference in relative transmissibility was due mostly to innate properties of Delta’s infectiousness or differences in the study populations. To investigate, we formed a partnership with SARS-CoV-2 genomic surveillance programs from all six New England US states. By comparing logistic growth rates, we found that Delta emerged 37-163% faster than Alpha in early 2021 (37% Massachusetts, 75% New Hampshire, 95% Maine, 98% Rhode Island, 151% Connecticut, and 163% Vermont). We next computed variant-specific effective reproductive numbers and estimated that Delta was 58-120% more transmissible than Alpha across New England (58% New Hampshire, 68% Massachusetts, 76% Connecticut, 85% Rhode Island, 98% Maine, and 120% Vermont). Finally, using RT-PCR data, we estimated that Delta infections generate on average ∼6 times more viral RNA copies per mL than Alpha infections. Overall, our evidence indicates that Delta’s enhanced transmissibility could be attributed to its innate ability to increase infectiousness, but its epidemiological dynamics may vary depending on the underlying immunity and behavior of distinct populations.Competing Interest StatementNDG is a paid consultant for Tempus Labs for work unrelated to this manuscript and has received speaking fees from Goldman Sachs. Funding StatementThis work was funded by CTSA Grant Number TL1 TR001864 (R.E. and M.E.P.), Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (N.D.G.), the Centers for Disease Control and Prevention (CDC) Broad Agency Announcement # 75D30120C09570 (N.D.G.) and # 75D30120C09605 (B.L.M), and CDC Baseline Surveillance Contract # 75D30121C10501 (Clinical Research Sequencing Platform, LLC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale University (Connecticut) The Institutional Review Board from the Yale University Human Research Protection Program determined that the RT-qPCR testing and sequencing of de-identified remnant COVID-19 clinical samples obtained from clinical partners conducted in this study is not research involving human subjects (IRB Protocol ID: 2000028599). Jackson Laboratory (Connecticut) The Institutional Review Board of The Jackson Laboratory determined that use of de-identified residual COVID-19 clinical samples obtained from the Clinical Genomics Laboratory for RT-qPCR testing and sequencing for this study is not research involving human subjects (IRB Determination: 2020-NHSR-021). Mass General Brigham (Massachusetts) The Institutional Review Board of Partners Human Research determined that the use of excess, de-identified COVID-19 clinical specimens obtained within the Partners Healthcare network for RT-qPCR testing and genomic sequencing for this study is not research involving human subjects (IRB Protocol ID: 2019P003305). In addition, the Institutional Review Board of the Massachusetts Department of Public Health has reviewed and approved this study to perform genomic sequencing of coronaviruses (IRB Protocol ID: 1603078). Health and Environmental Testing Laboratory (Maine) A Memorandum of Understanding between The State of Maine Department of Health and Human Services and The Jackson Laboratory determined that extracted viral RNA from human respiratory specimens which have tested positive for SARS-CoV-2 and are used for sequencing will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA summary of the SARS-CoV-2 lineages used from GISAID are available in Tables S1-S3 and a complete list of GISAID acknowledgements are available in Data S1-S7. All other publicly available data and code used for this paper are available on github (https://github.com/grubaughlab/2021_paper_Delta-v-Alpha). https://github.com/grubaughlab/2021_paper_Delta-v-Alpha